The word chemotherapy carries significant weight. For many patients, it is one of the most feared aspects of a breast cancer diagnosis, conjuring images of hair loss, severe nausea, and weeks of debilitation. The reality of modern breast cancer chemotherapy is considerably more nuanced than this — for many patients, treatment is manageable, side effects are far better controlled than in previous generations, and the benefits in terms of reducing the risk of recurrence and improving survival are substantial and well-established.

Understanding what chemotherapy is, when it is recommended, how it is given, and what to expect can make an enormous difference to how prepared and in control you feel. At Breast & Surgical Oncology at The Poche Centre, our surgeons work in close collaboration with specialist medical oncologists to ensure every patient who requires chemotherapy is supported through it with the best available care and information.

What Is Chemotherapy?

Chemotherapy refers to a group of drugs, called cytotoxic agents, that kill or inhibit the growth of rapidly dividing cells. Cancer cells divide more rapidly and less accurately than normal cells, which makes them particularly susceptible to these agents. The drugs travel through the bloodstream and reach cancer cells throughout the body, which is why chemotherapy is effective not just at the primary tumour site but anywhere in the body that cancer cells may have spread.

Most commonly, chemotherapy for breast cancer is delivered intravenously through a drip into a vein. Some agents can be given as tablets. Treatment is delivered in cycles, with rest periods between each cycle to allow the body to recover. A full course of adjuvant chemotherapy for breast cancer typically involves between four and eight cycles, administered over three to six months.

Because chemotherapy affects all rapidly dividing cells, not just cancer cells, it also temporarily affects other rapidly proliferating tissues in the body, particularly the hair follicles, the lining of the gut, the bone marrow, and the mouth. This is the basis of most of the side effects associated with treatment. Importantly, these effects are temporary — normal cells recover fully between cycles and after treatment ends.

Who Needs Chemotherapy for Breast Cancer?

Not every patient with breast cancer requires chemotherapy. The decision is based on an individual assessment of the cancer's biology and the likely benefit of treatment, weighed against its side effects and impact on quality of life.

Chemotherapy is most clearly indicated for certain groups of patients. These include those with HER2-positive breast cancer, where chemotherapy is given alongside anti-HER2 targeted therapies; those with triple-negative breast cancer, which is not responsive to hormonal therapies and for which chemotherapy remains the principal systemic treatment; those with lymph node involvement, where chemotherapy reduces the risk of distant recurrence; those with high-grade (grade 3) tumours that are biologically aggressive; and those with larger tumours.

For hormone receptor-positive, HER2-negative breast cancers, the picture is more complex. This is where genomic testing has had its greatest impact on clinical practice.

The role of genomic testing in chemotherapy decisions

For patients with early-stage, hormone receptor-positive, HER2-negative breast cancer, genomic tests such as Oncotype DX and Prosigna analyse the activity of multiple genes within the tumour to generate a recurrence risk score. This score predicts the likelihood of the cancer returning at a distant site and, critically, whether chemotherapy is likely to add meaningful benefit over hormonal therapy alone.

Landmark clinical trials have demonstrated that patients with a low recurrence score can safely forgo chemotherapy without compromising their survival outcomes. This means some patients who would previously have been recommended chemotherapy are now able to avoid it, sparing them the side effects and toxicity of treatment they would not benefit from. For those with a higher recurrence score, the genomic data provides stronger evidence that chemotherapy will improve outcomes.

Our team incorporates genomic testing into chemotherapy decision-making for appropriate patients, ensuring every recommendation is as personalised and evidence-based as possible.

Adjuvant vs. Neoadjuvant Chemotherapy

Chemotherapy can be given either after surgery (adjuvant chemotherapy) or before surgery (neoadjuvant chemotherapy). Both approaches use the same drugs and achieve the same systemic effect; the difference is timing and the additional information that neoadjuvant treatment provides.

Adjuvant chemotherapy is the traditional approach and is given after surgery to eliminate any microscopic residual cancer cells that may have spread beyond the breast before surgery. It significantly reduces the risk of distant recurrence in patients for whom it is recommended.

Neoadjuvant chemotherapy is given before surgery and is increasingly used in breast cancer management for several important reasons. It can shrink a large tumour to make breast-conserving surgery possible where mastectomy would otherwise be required. It treats the systemic disease early, when cancer cells may be most vulnerable. It allows real-time assessment of how the tumour responds to treatment, providing valuable prognostic information. A complete pathological response (no residual cancer found in the surgical specimen after neoadjuvant treatment) is associated with an excellent long-term prognosis, particularly in HER2-positive and triple-negative breast cancers.

Neoadjuvant chemotherapy may be recommended in the following circumstances: when the tumour is too large to be safely removed without prior shrinkage; when inflammatory breast cancer is present; to enable breast-conserving surgery instead of mastectomy; to reduce lymph node disease and avoid the need for full axillary clearance; to allow time for genetic testing or surgical planning; to enable access to clinical trials that may offer benefit beyond standard chemotherapy; when there is a strong family history and genetic testing results may influence surgical decisions; and when chemotherapy during pregnancy is clinically needed to allow the pregnancy to continue to near term.

When a tumour responds completely to neoadjuvant chemotherapy and disappears on imaging, a small titanium clip placed in the tumour at the time of biopsy (or before commencing treatment) marks the original site so the surgeon can precisely identify and remove it at the time of operation.

Common Chemotherapy Regimens in Breast Cancer

Several different chemotherapy regimens are used in breast cancer depending on the cancer subtype, stage, and whether treatment is given before or after surgery. Your medical oncologist will recommend the most appropriate regimen for your situation. Commonly used regimens include the following.

Anthracycline-based regimens (using drugs such as doxorubicin or epirubicin) are foundational in breast cancer chemotherapy and are often combined with cyclophosphamide. They are highly effective at killing cancer cells and are used in both adjuvant and neoadjuvant settings. Anthracyclines carry a small long-term risk of effects on heart function, which your oncologist will monitor.

Taxane-based regimens (using docetaxel or paclitaxel) are commonly added to anthracycline-based treatment or used sequentially, particularly in HER2-positive and triple-negative breast cancers. Taxanes can cause peripheral neuropathy (numbness or tingling in the hands and feet) which is usually temporary.

AC-T and EC-T regimens combine an anthracycline (doxorubicin/A or epirubicin/E) with cyclophosphamide/C, followed by a taxane (T). This is one of the most widely used sequences for breast cancer chemotherapy.

TCH (docetaxel, carboplatin, and trastuzumab) is a commonly used regimen for HER2-positive breast cancer, combining chemotherapy with the targeted anti-HER2 agent trastuzumab.

Capecitabine is an oral chemotherapy agent used in the adjuvant setting for triple-negative breast cancer patients who did not achieve a complete pathological response to neoadjuvant treatment (as part of the CREATE-X trial evidence), and in selected other settings.

How Is Chemotherapy Administered?

Most breast cancer chemotherapy is administered intravenously in a dedicated day chemotherapy unit. A cannula is inserted into a vein in the arm for each session, or for patients who require multiple cycles or have difficult venous access, a central venous access device such as a PICC line or implanted port (portacath) can be placed to make repeated access easier and more comfortable.

Each treatment session, or cycle, typically takes between one and several hours in the chemotherapy unit. Between cycles, you go home and live your normal life as much as possible, returning for the next cycle according to the schedule your oncologist has set. Most regimens involve treatment every two to three weeks.

Before each cycle, blood tests are performed to check your blood counts and organ function. Your medical oncologist reviews these results and assesses how you are tolerating treatment before proceeding with the next cycle. If your counts are significantly low or you are experiencing significant side effects, a cycle may be delayed or the dose adjusted.

Managing Side Effects

Modern supportive care for chemotherapy side effects has improved dramatically compared to even a decade ago. Many of the most feared side effects can now be substantially prevented or managed, and your medical oncology team will work proactively with you throughout treatment to minimise their impact.

Nausea and vomiting are among the most commonly anticipated side effects, but are now very effectively controlled in most patients with modern antiemetic medications given before and after chemotherapy. Severe, uncontrolled nausea is far less common than it once was.

Fatigue is one of the most consistently reported and often most challenging side effects. It tends to be worst in the days immediately following each cycle and generally improves before the next. Gentle, regular exercise, even short walks, has been shown to help manage cancer-related fatigue. Prioritising rest and pacing activities across the cycle is important.

Hair loss (alopecia) occurs with many but not all chemotherapy regimens used in breast cancer. Where it occurs, hair loss is temporary and hair grows back after treatment is complete, though the texture or colour may initially be different. Scalp cooling, applied during chemotherapy infusions, reduces hair loss in a proportion of patients receiving certain regimens and may be discussed with your oncology team as an option.

Increased infection risk (neutropenia) occurs because chemotherapy temporarily reduces white blood cell counts. Your oncologist may prescribe growth factor injections (G-CSF) to stimulate white cell recovery, and will advise you on what symptoms warrant immediate medical attention (particularly fever, which may indicate neutropenic sepsis, a medical emergency requiring prompt hospital assessment).

Peripheral neuropathy (numbness, tingling, or pain in the hands and feet) is associated particularly with taxane-based regimens. It is often temporary but can persist. Reporting symptoms early allows your oncologist to adjust treatment if needed.

Mouth sores (mucositis) can occur with some regimens. Good oral hygiene and regular mouth rinses help reduce severity.

Menopausal symptoms including hot flushes, night sweats, and vaginal dryness may be induced or worsened by chemotherapy, particularly in premenopausal women. These can be managed with a range of measures and should be discussed with your team.

Chemobrain (cognitive fogginess or difficulty with memory and concentration) is reported by many patients during and after chemotherapy and generally improves after treatment ends.

Long-term effects to discuss with your oncologist include effects on heart function (with anthracyclines), effects on fertility (see below), and the very small risk of treatment-related secondary cancers with some regimens.

Fertility and Chemotherapy

For premenopausal women who wish to preserve the option of future pregnancy, fertility preservation should be discussed with your oncology team before starting chemotherapy. Chemotherapy can temporarily or permanently affect ovarian function and fertility, and the impact varies with regimen, age, and individual ovarian reserve.

Embryo and egg freezing (oocyte cryopreservation) are the most established fertility preservation options and are ideally arranged before chemotherapy begins. A fertility specialist can be involved quickly as part of the treatment planning process in most centres. Ovarian suppression with GnRH agonists during chemotherapy may also reduce the risk of chemotherapy-induced ovarian failure and is increasingly used alongside fertility preservation.
If fertility preservation is a concern for you, please raise it with your surgeon or medical oncologist as early as possible so appropriate arrangements can be made without delaying treatment.

Practical Tips for Managing Chemotherapy

Going through chemotherapy is a significant undertaking. A few practical approaches that many patients find helpful include planning your schedule around your cycle so you have support during the days when you are most likely to feel unwell; arranging help at home, especially if you have young children; informing your employer early about the likely impact on your work capacity and exploring flexible arrangements; connecting with your breast care nurse as a consistent point of support throughout treatment; keeping a symptom diary to help your oncology team adjust your management; staying hydrated and eating as well as you can manage; and avoiding raw or undercooked foods during periods when your immune system is most suppressed.

Chemotherapy as Part of Your Multidisciplinary Care

At Breast & Surgical Oncology at The Poche Centre, our surgeons work alongside specialist medical oncologists who lead chemotherapy planning and delivery. Your case is discussed at the multidisciplinary team meeting before treatment begins, ensuring your chemotherapy plan is fully integrated with your surgical care and all other aspects of your treatment.

We remain involved throughout your chemotherapy and are always available to address any breast surgery-related questions or concerns that arise during treatment.